"label","uuid:ID","name","description","instanceType","rationale","id"
"","a019cb6d-7525-4583-ad52-1a8b6eab7de1","Study Design 1","The main design for the study","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1"
